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Background: Since the introduction of medium-chain acyl coenzyme A dehydrogenase (MCAD) deficiency in
population newborn bloodspot screening (NBS) programs, subjects have been identified with variant ACADM (gene
encoding MCAD enzyme) genotypes that have never been identified in clinically ascertained patients. It could be
hypothesised that residual MCAD enzyme activity can contribute in risk stratification of subjects with variant ACADM
genotypes.
Methods: We performed a retrospective cohort study of all patients identified upon population NBS for MCAD
deficiency in the Netherlands between 2007–2010. Clinical, molecular, and enzymatic data were integrated.
Results: Eighty-four patients from 76 families were identified. Twenty-two percent of the subjects had a variant
ACADM genotype. In patients with classical ACADM genotypes, residual MCAD enzyme activity was significantly
lower (median 0%, range 0-8%) when compared to subjects with variant ACADM genotypes (range 0-63%; 4 cases
with 0%, remainder 20-63%). Patients with (fatal) neonatal presentations before diagnosis displayed residual MCAD
enzyme activities <1%. After diagnosis and initiation of treatment, residual MCAD enzyme activities <10% were
associated with an increased risk of hypoglycaemia and carnitine supplementation. The prevalence of MCAD
deficiency upon screening was 1/8,750 (95% CI 1/7,210–1/11,130).
Conclusions: Determination of residual MCAD enzyme activity improves our understanding of variant ACADM
genotypes and may contribute to risk stratification. Subjects with variant ACADM genotypes and residual MCAD
enzyme activities <10% should be considered to have the same risks as patients with classical ACADM genotypes.
Parental instructions and an emergency regimen will remain principles of the treatment in any type of MCAD
deficiency, as the effect of intercurrent illness on residual MCAD enzyme activity remains uncertain. There are,
however, arguments in favour of abandoning the general advice to avoid prolonged fasting in subjects with variant
ACADM genotypes and >10% residual MCAD enzyme activity.
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Medium-chain acyl-Coenzyme A dehydrogenase (MCAD
[E.C.1.3.99.3]) deficiency (OMIM 201450) is the most
common inherited disorder of mitochondrial fatty acid
oxidation. The MCAD enzyme is responsible for the first
step in the mitochondrial β-oxidation of CoA esters of
medium-chain length fatty acids [1].
Before the introduction of population newborn bloodspot
screening (NBS) for MCAD deficiency, patients presented
clinically during periods of catabolic stress, precipitating
acute symptoms [2,3]. Some patients developed seizures,
coma or even presented with sudden death, associated with
hypoketotic hypoglycaemia. However, asymptomatic family
members have also been recognized with the same disease-
causing genotype [4]. Worldwide, approximately 80% of
clinically presenting patients were homozygous for the
c.985A>G missense mutation in the ACADM gene enco-
ding the MCAD enzyme [5]. Early diagnosis significantly
improves the outcome [3] and treatment is mainly dietary,
consisting of avoidance of prolonged fasting and an emer-
gency regimen during intercurrent illness [6]. Secondary
free carnitine (C0) deficiency in blood may be corrected by
carnitine supplementation in some patients, but evidence
for this treatment is limited [7].
Since the introduction of the NBS programs, newborns
are identified by the detection of increased concentrations
of medium-chain length acylcarnitines and their ratios [8].
An elevated concentration of octanoylcarnitine (C8:0) is the
most common biomarker for MCAD deficiency. Besides
patients with classical ACADM genotypes, NBS identifies
subjects with hyperoctanoylcarnitinaemia and variant
ACADM genotypes, i.e. genotypes that have not been recog-
nized before in clinically ascertained patients [9]. As popula-
tion NBS programs aim to prevent development of a
phenotype, physicians feel forced to institute treatment,
independent of the genotype. It can be questioned, however,
whether subjects with variant ACADM genotypes have the
same clinical risks compared to patients with classical
ACADM genotypes. Or even, whether they should be
regarded patients at all. Different studies used laboratory
parameters to estimate the significance of variant ACADM
genotypes [10-14]. Clinical follow-up parameters are diffi-
cult to interpret, because early diagnosis and treatment
influence the natural clinical course of subjects with variant
ACADM genotypes.
It could be hypothesised that residual MCAD enzyme
activity is a prognostic parameter in risk stratification of
patients with variant ACADM genotypes. Therefore, we
performed a cohort study integrating NBS test results,
molecular studies, and clinical data with enzymatic
data of all patients from the Dutch birth cohorts
2007–2010 identified in the population NBS program
for MCAD deficiency. The results from subjects with
variant ACADM genotypes were stratified, using datafrom patients with classical ACADM genotypes as a
reference.
Patients and methods
The Medical Ethical Committee of the University Medical
Centre Groningen approved the study (METc 2011/133).
Parents provided written informed consent.
Population NBS protocol
In The Netherlands, the epidemiology and natural his-
tory of MCAD deficiency have been well characterised
before introduction of the population NBS program in
2007 [2,4,15]. In our country, 99.75% of all newborns are
screened between 72 and 168 h after birth (www.rivm.nl).
In dried blood spots the following parameters are deter-
mined: concentrations of C0, C8:0, and decanoylcarnitine
(C10:0), and the C8:0/C10:0 ratio. For MCAD deficiency,
the decision is based on the C8:0 concentration only as
clinical and laboratory follow-up is initiated in newborns
with C8:0≥ 0.50 μmol/l within 24 h.
Protocol for laboratory follow-up
After an initial positive NBS test for MCAD deficiency,
the newborns are referred to a metabolic centre. Labora-
tory follow-up includes a complete acylcarnitine profile
in plasma and/or a dried blood spot by tandem mass-
spectrometry, and urinary organic acid analysis using gas
chromatography–mass spectrometry, as described by
Derks et al. [9]. Determination of MCAD enzyme activity
is performed in leukocytes or lymphocytes, with an
HPLC-based assay using 3-phenylpropionyl-CoA (PP-
CoA) as a substrate [9,16]. Residual MCAD enzyme ac-
tivities are expressed as percentage from healthy con-
trols. Analysis of the ACADM gene (OMIM 607008) is
performed by sequencing all exons and adjacent intron
regions. The nucleotide numbering starts from the first
adenine of the ATG translation initiation codon of the
ACADM cDNA sequence and amino acid numbering
starts from the methionine encoded by this translation
initiation codon. The abovementioned analyses are pre-
ceded by parental informed consent.
A ‘variant ACADM genotype’ was defined as an ACADM
genotype that has not been recognized before in clinically
ascertained patients in either The Netherlands [2] or in
literature.
Cohort
In this study, we included children from the Dutch birth
cohorts 2007–2010 with clinical follow-up in a metabolic
centre after population NBS for MCAD deficiency. For
most children the diagnosis has been confirmed by
MCAD enzyme and/or ACADM gene analysis. If these
analyses were not performed, the confirmatory acylcarni-
tine profile was characterised by C8:0 concentrations >50
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z-scores (i.e. ≥ 8.3) above the threshold for NBS, based on
reference data from the National Institute for Public
Health and the Environment.
Clinical and laboratory data from all patients were
retrospectively retrieved from the Dutch Diagnosis
Registration Metabolic Diseases database (www.ddrmd.
nl), and medical and laboratory files by one investiga-
tor (CT). Data from the patients in which the diagno-
sis had been confirmed enzymatically were included
in the analysis of the prognostic value of MCAD en-
zyme analysis.
Data analysis
Using data from the Dutch Central Bureau for Statistics
(CBS) (www.cbs.nl), the prevalence P was calculated by
dividing the total number of patients by the total number
of newborns N. For calculation of the 95% confidence
interval (95% CI) the following formula was used:
95%CI ¼ P 1:96  P 1 Pð Þð Þ=Nð Þ1=2
Differences between normally distributed continuous data
were analyzed using parametric tests. Data that were not
normally distributed were analyzed using nonparametric
tests. For dichotomous data, a chi-squared test was used.
For analysis of correlations, Spearman’s rank test was used.
The significance level was set at p< 0.05. Statistical analyses
were performed using GraphPad Prism software (GraphPad
Software Inc., version 5.00, 2007).
Results
Cohort
In the period 2007–2010, the diagnosis MCAD defi-
ciency was confirmed in 84 patients, after 108 initial
positive screening results for C8:0 ≥ 0.50 μmol/l. Data
from the NBS test, molecular studies and clinical follow-
up were compared to the residual MCAD enzyme activity,
in order to determine the prognostic value. Results from
patients with a classical ACADM genotype were used as a
reference.
Relationship between ACADM genotypes and residual
MCAD enzyme activities
ACADM genotypes were available from 68 of the 84
patients (Table 1). Homozygosity for the common
c.985A>G mutation was observed in 62% (42/68),
the c.985A>G allele frequency was 77% (104/136).
Variant ACADM genotypes were observed in 22% (15/
68).
Data on residual MCAD enzyme activity could be
obtained from 64 of the 84 patients. Median residual
MCAD enzyme activity in patients with classical
ACADM genotypes was 0% (range 0-8% and 0-5% inleukocytes and lymphocytes, respectively). Subjects
with variant ACADM genotypes displayed significantly
higher MCAD residual enzyme activities (median 25%,
range 0-63%, Mann–Whitney U test, p< 0.01)
(Figure 1).
For further comparison of groups, patients were stratified
based on residual MCAD enzyme activity. A threshold of
10% was considered practical and safe, because the highest
residual MCAD enzyme activity determined in a patient
with a classical ACADM genotype was 8%.Relationship between population NBS test results and
MCAD enzyme activities
Figure 2a demonstrates that C8:0 concentrations were sig-
nificantly higher in patients with residual MCAD enzyme
activities <10% than in subjects with residual MCAD en-
zyme activities ≥10% (median 3.96, range 0.77–
14.80 μmol/l vs. median 1.11, range 0.56– 2.82 μmol/l, re-
spectively, Mann–Whitney U test, p< 0.01). Additionally,
C8:0/C10:0 ratios were significantly higher in the group of
patients with residual MCAD enzyme activities <10%
(median 13.00, range 3.21–18.50), when compared to the
group of subjects with residual MCAD enzyme activities
≥10% (median 3.41, range 1.81–8.03, Mann–Whitney U
test, p< 0.01). A strong negative linear correlation was
found between the NBS C8:0/C10:0 ratio and the residual
MCAD enzyme activity measured in lymphocytes (Spear-
man r =−0.67, p< 0.001) (Figure 2b).Relationship between clinical phenotypes and MCAD
enzyme activities
Seven newborns had a clinical presentation in the neo-
natal period before diagnosis (Table 2). Two of these
newborns died before arrival in the hospital. Five had
been admitted to the hospital before NBS test results be-
came available, three of them with documented
hypoglycaemia. All newborns with a neonatal presenta-
tion had a C8:0/C10:0 ratio ≥10 upon NBS and residual
MCAD enzyme activities <1%. Six of these patients had
a classical ACADM genotype. The seventh case had the
variant c.985A>G/c.216+1G>T genotype, corresponding
with 0% residual MCAD enzyme activity.
After the diagnosis was established, no fatal mani-
festations of MCAD deficiency were reported. Patients
with residual MCAD enzyme activities <10% were 1.2
times more frequently admitted to the hospital pre-
ventively, compared to subjects with residual MCAD
activities ≥10% (Table 2). All patients with documen-
ted hypoglycaemia had residual MCAD enzyme activ-
ities <10%. During follow-up, no carnitine was
prescribed for low plasma C0 concentrations in sub-
jects with residual MCAD enzyme activities ≥10%. In
contrast, 51% (27/51) of the patients with residual
Table 1 ACADM genotypes in 68 patients, identified upon population NBS for MCAD deficiency in The Netherlands












CLASSICAL 42 c.985A>G 11 p.K329E c.985A>G 11 p.K329E 0 0 [25-27]
5 c.985A>G 11 p.K329E c.233 T>C 4 p.I78T 2 2 [23]
2 c.985A>G 11 p.K329E c.789A>G 9 p.L263F 0 n.d. [2]
1 c.985A>G 11 p.K329E c.799 G>A 9 p.G267R 8 n.d. [28,29]
2 c.233 T> C 4 p.I78T c.233 T>C 4 p.I78T <1 3 [23]
1 c.233 T> C 4 p.I78T c.789A>G 9 p.L263F 0 n.d. [2,23]
VARIANT 2 c.985A>G 11 p.K329E c.158 G>A 3 p.R53H n.d. 23 This study
3 c.985A>G 11 p.K329E c.199 T>C 3 p.Y67H 58 31 [30]
1 c.985A>G 11 p.K329E c.216 + 1 G> T 4 Splice site
variant
n.d. 0 This study
2 c.985A>G 11 p.K329E c.238A>G 4 p.R80G n.d. 36 This study
1 c.985A>G 11 p.K329E c.470 C> T 7 p.A157V n.d. 0 This study
1 c.985A>G 11 p.K329E c.493 G>A 7 p.A165T n.d. 20 This study
1 c.985A>G 11 p.K329E c.600-18 G>A 8 p.XXX? n.d. 63 [10]
1 c.985A>G 11 p.K329E c.928 G>A 10 p.G285R 0 n.d. [23]
1 c.233 T> C 4 p.I78T c.1066A> T 11 p.I356F n.d. 0 This study
1 c.250 C> T 4 p.L84F c.199 T>C 3 p.Y67H n.d. 58 [30,31]
1 c.799 G>A 9 p.G267R c.865 G>A 10 p.V289I n.d. 25 This study
A, measured in leukocytes; B, measured in lymphocytes; n.d., not determined. Median residual MCAD enzyme activities are depicted.
Figure 1 Residual MCAD enzyme activities measured in
leukocytes, and lymphocytes. Legend: Residual MCAD enzyme
activities measured in leukocytes (A), and lymphocytes (B) from true
positives with variant ACADM genotypes (squares) and classical
ACADM genotypes (dots).
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supplementation.
Epidemiology
Between 2007–2010, 84 patients were identified from 76
families. The prevalence of MCAD deficiency was 1/8,750
(95%CI 1/7,210–1/11,130), which is considered to be a high
estimate (Table 3). When subjects with residual MCAD ac-
tivities ≥10% were excluded, the prevalence was 1/10,070
(95%CI 1/8,190-1/13,070).
Discussion
This is the first report in which residual MCAD enzyme
activities in a large cohort of patients identified upon
population NBS for MCAD deficiency have been used
for risk stratification. Within the group of newborns with
hyperoctanoylcarnitinaemia, a broad spectrum of ACADM
genotypes has been identified. As the clinical significance of
many variant ACADM genotypes is incompletely known,
we integrated clinical, molecular and enzymatic data from a
well-defined population. Residual MCAD enzyme activity
correlated well with ACADM genotype and phenotype, and
could therefore aid in the risk stratification of patients after
positive NBS test.
In this study, residual MCAD enzyme activity was mea-
sured with PP-CoA, which is a very specific substrate todetermine residual MCAD enzyme activity in vitro [16,17].
Traditionally, natural substrates such as hexanoyl-CoA and
octanoyl-CoA were used to determine MCAD enzyme ac-
tivity. However, even in patients who were homozygous for
the classical c.985A>G ACADM mutation, high residual
enzyme activities were found when using these substrates,
ab
Figure 2 Relationship between residual MCAD enzyme activity
and C8:0 and C8:0/C10:0 ratio upon NBS. Legend: Classical
ACADM genotypes depicted in black, variant ACADM genotypes in
grey. Squares: measured in leukocytes; Circles: measured in
lymphocytes.
Table 2 Prevalence of clinical symptoms and
interventions in patients, organised by residual MCAD
enzyme activity
Residual MCAD enzyme activity
< 10% ≥ 10%
Neonatal presentation (%) 13% (7/53) 0%
Hypoglycaemia (%) 8% (4/51) 0%
Carnitine supplementation (%) 51% (27/51) 0%
Patients with hospital admissions (%) 82% (42/51) 55% (6/11)*
Hospital admissions (n) 116 14*
Hospital admissions per life year 0.64/life year 0.55/life year
Data were processed as described in ‘Patients and Methods’. Hypoglycaemia
was defined as blood glucose concentration <2.6 mmol/L or reported
hypoglycaemia in medical charts. * p< 0.05.
Table 3 Epidemiology of MCAD deficiency in The
Netherlands before and after the introduction of
population NBS
MCAD deficiency in The Netherlands Frequencies (95% CI)
ACADM mutation carrier frequencya 1/55 (1/46 – 1/68)
Expected prevalencea 1/12,100 (1/8,450 – 1/18,500)
Observed prevalence 1985-1999b 1/27,400 (1/23,000 – 1/33,900)
Screened newborns 2007-2010c 735,282
Patients 2007-2010d 84
Prevalence upon neonatal screeningd 1/8,750 (1/7,210 – 1/11,130)
a According to De Vries et al. [15]; b According to Derks et al. [4]; c According
to CBS; d This study.
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other acyl-CoA dehydrogenases [9]. Therefore, in our coun-
try these substrates have been replaced in the confirmatory
enzymatic studies after positive NBS test results. However,
the possible role of PP-CoA in the pathophysiology of
MCAD deficiency is currently unknown and it is important
to realise that the pathophysiology is far more complex than
just deficient MCAD enzyme activity.
Before NBS test results became available, a neonatal
presentation occurred in seven patients with residual
MCAD enzyme activities <1%. Two of these patients
presented with a fatal event. Despite the important bene-
fits of population NBS programs for MCAD deficiency
[3], the question remains justified, whether we detect all
patients before clinical presentation and whether they
are all patients. When compared to other NBS programs,
blood sampling for the NBS test is relatively late in our
country, i.e. between 72 and 168 hours of life. However,similar percentages of (fatal) neonatal presentations have
been reported in studies from other countries, where the
NBS test is performed earlier in the neonatal period [3].
Since several inherited metabolic diseases may present with
a fatal neonatal presentation, escaping early detection by
population NBS programs, we recommend dried blood spot
analysis of acylcarnitines and amino acids in all newborns
who die before the NBS test has been performed.
In a subset of the children with variant ACADM geno-
types, residual MCAD enzyme activity is relatively high
(Table 1). This raises the question whether these subjects
are at risk of developing clinical symptoms as patients with
classical genotypes, and should be considered “patients”. If
the main arguments for a population NBS program are
strictly considered [18], subjects with variant ACADM gen-
otypes may not be regarded “true-positives”, because their
genotypes have not been observed before in clinically
ascertained patients. However, some of these mutations
may have never been detected due to low carrier frequen-
cies, but may give the same clinical risks as classical
ACADM mutations [19]. Already before the introduction
of NBS for MCAD deficiency, the term “patient” was a
matter of debate. Reduced penetrance of the disorder is a
well-recognised phenomenon, reflected by asymptomatic
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as clinically ascertained probands [4]. Moreover, it is recog-
nised that single nucleotide polymorphisms (in combination
with a classical ACADM mutation) may contribute to the
development of hyperoctanoylcarnitinaemia by modulating
mitochondrial fatty acid oxidation [19].
In this study, 15 subjects had a ‘variant ACADM geno-
type’. Three newborns (with c.985A>G/c.216+1G>T;
c.985A>G/c.470C>T and c.233T>C/c.1066A>T geno-
types) displayed C8:0/C10:0 ratios >10 and residual
MCAD enzyme activity <1% (Figure 2b), as observed in
patients with classical ACADM genotypes. In our opinion,
they should be considered and treated like patients with
classical ACADM genotypes. The patient with the
c.985A>G/c.928G>A genotype displayed a C8:0/C10:0
ratio <10. Since MCAD enzyme activity was absent, he was
considered “patient” like patients with classical ACADM
genotypes. In the remaining 11 subjects with variant
ACADM genotypes, residual MCAD enzyme activities ran-
ged between 20%–63%. Should they receive (the same)
treatment as patients with classical genotypes? In previous
studies that aimed to determine risk stratification for sub-
jects with variant ACADM genotypes, different sets of data
have been used. Examples include correlation of metabolite
concentrations to ACADM genotypes [10,11], or heterolo-
gous overexpression studies to determine the effect of
various ACADM mutations on residual MCAD enzyme
activity and the thermal stability of the MCAD enzyme
[12-14]. In most cases, however, the effect of one single
ACADM mutation was studied, although MCAD deficiency
is an enzyme deficiency caused by genetic alterations on
both ACADM alleles.
In this study, classical ACADM genotypes were
associated with residual MCAD enzyme activities
<10%. Substantial octanoate oxidation [20] and nor-
mal ketone body metabo-lism [21] were demon-
strated in previous stable isotope studies under
normal fasted conditions in patients with classical
ACADM genotypes. It is well recognised that
clinically ascertained patients tolerated overnight
fasting without problems before establishment of the
diagnosis, as recently reviewed [22]. Similar observa-
tions were made in our country, since overnight fasting per
se has never precipitated symptoms in patients [2,6]. As a
subset of subjects with variant ACADM genotypes was
associated with a milder biochemical and clinical pheno-
type, and relatively high residual MCAD enzyme activity, it
could be argued that the general advice on avoidance of
overnight fasting in subjects with residual MCAD enzyme
activities ≥10% can be abandoned. However, the major
argument in favour of avoiding prolonged fasting is early
anticipation in circumstances of intercurrent illness with
fever in young patients. Some (variant) ACADM mutations
have shown to lead to temperature sensitive MCADfolding variants in vitro [14,23]. The clinical in vivo effects
remain to be determined. Therefore, an emergency regi-
men and clinical follow-up remain basic principles of the
treatment, regardless of ACADM genotype.
The prevalence of MCAD deficiency upon NBS in The
Netherlands is threefold higher than found after clinical
presentation (Table 3) [4], and in line with previous reports
[24]. Prior to the introduction of the NBS program, the
expected prevalence of MCAD deficiency was calculated to
be 1/12,100 (95%CI: 1/8,450–1/18,500) in our country,
based on the ACADM c.985A>G carrier frequency in the
general population and the assumption of a 94% allele fre-
quency for this common mutation in clinically ascertained
cases [15]. The latter was confirmed in patients from the
Dutch birth cohorts 1985–1999 [4]. The current study dis-
plays a more heterogeneous ACADM mutational spectrum
with an observed allele frequency of the c.985A>G
ACADM mutation of only 77%. Although the observed
prevalence is comparable to the expected prevalence [15], it
is important to realize that the availability of molecular tests
for the complete ACADM gene has significantly increased
since the 1990s. This might have biased identification of
patients in our previous studies, hence, causing an under-
estimation of the expected prevalence. In addition, demo-
graphic alterations within the same geographic area might
have contributed (www.cbs.nl).Conclusions
Population-wide NBS programs identify newborns with
hyperoctanoylcarnitinaemia and variant ACADM geno-
types. These newborns are currently regarded patients, in
whom follow-up and dietary treatment are initiated simi-
larly to the group with classical ACADM genotypes. This
study demonstrates the prognostic value of residual
MCAD enzyme activity in newborns with hyperoctanoyl-
carnitinaemia and a variant ACADM genotype. Residual
MCAD enzyme activities <10% were associated with clin-
ical symptoms, regardless of ACADM genotype. Clinical
symptoms or classical ACADM genotypes have thus far not
been reported in subjects with residual MCAD enzyme ac-
tivities ≥10%. For all positively screened newborns with any
form of MCAD deficiency, basic principles of the treatment
are parental instructions, cautious clinical follow-up, and
application of an emergency regimen. In subjects with
variant ACADM genotypes and ≥10% residual MCAD en-
zyme activities, the necessity to avoid overnight fasting is
debatable.Abbreviations
ACADM: Gene encoding medium-chain acyl-CoA dehydrogenase; C0: Free
carnitine; C8:0: Octanoylcarnitine; C10:0: Decanoylcarnitine; C8:0/C10:0: Ratio
between octanoylcarnitine and decanoylcarnitine concentrations;
MCAD: Medium-chain acyl-CoA dehydrogenase; NBS: Newborn bloodspot
screening; PPA: Phenylpropionic acid; PP-CoA: Phenylpropionyl-CoA.
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